anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: This study aims to identify the disability specialists currently needed for students with vision or hearing impairment in the United Arab Emirates (UAE). It also aims to identify the university-level training courses available for these specialists.
MATERIALS AND METHODS: This study adopted a mixed-methods design. The qualitative strand involved a thematic analysis of semi-structured interviews conducted with 20 employees of 10 UAE organizations providing support services to students with vision or hearing impairment. The quantitative strand determined the number of disability-related degree courses offered at UAE universities from 2018 to 2020.
RESULTS: The interviewees revealed that students with visual impairment most need teachers for the visually impaired, braille trainers, orientation and mobility trainers, and assistive technology specialists, whereas students with hearing impairment most need teachers of the deaf or hard of hearing, speech therapists, and sign language specialists. Regarding disability-related training, 10 UAE universities each offered one disability-related programme between 2018 and 2020. These included nine general programmes for special or inclusive education and one programme for speech pathology.
CONCLUSION: UAE universities are currently unable to train the disability specialists required for students with vision or hearing impairment. An interim option is to offer scholarships to enable Emirati students planning to become disability specialists to gain these specialized qualifications overseas. Current efforts in the UAE to address the needs of people with disabilities should include a development and implementation plan for UAE university programmes to offer specialized courses for people with vision or hearing impairment.
PURPOSE: This study aims to broaden the application of nano-contrast agents (NCAs) within the realm of the musculoskeletal system. It aims to introduce novel methods, strategies, and insights for the clinical management of ischemic muscle disorders, encompassing diagnosis, monitoring, evaluation, and therapeutic intervention.
METHODS: We developed a composite encapsulation technique employing O-carboxymethyl chitosan (OCMC) and liposome to encapsulate NCA-containing gold nanorods (GNRs) and perfluoropentane (PFP). This nanoscale contrast agent was thoroughly characterized for its basic physicochemical properties and performance. Its capabilities for in vivo and in vitro ultrasound imaging and photothermal imaging were authenticated, alongside a comprehensive biocompatibility assessment to ascertain its effects on microcirculatory perfusion in skeletal muscle using a murine model of hindlimb ischemia, and its potential to augment blood flow and facilitate recovery.
RESULTS: The engineered GNR@OCMC-liposome/PFP nanostructure exhibited an average size of 203.18±1.49 nm, characterized by size uniformity, regular morphology, and a good biocompatibility profile. In vitro assessments revealed NCA's potent photothermal response and its transformation into microbubbles (MBs) under near-infrared (NIR) irradiation, thereby enhancing ultrasonographic visibility. Animal studies demonstrated the nanostructure's efficacy in photothermal imaging at ischemic loci in mouse hindlimbs, where NIR irradiation induced rapid temperature increases and significantly increased blood circulation.
CONCLUSION: The dual-modal ultrasound/photothermal NCA, encapsulating GNR and PFP within a composite shell-core architecture, was synthesized successfully. It demonstrated exceptional stability, biocompatibility, and phase transition efficiency. Importantly, it facilitates the encapsulation of PFP, enabling both enhanced ultrasound imaging and photothermal imaging following NIR light exposure. This advancement provides a critical step towards the integrated diagnosis and treatment of ischemic muscle diseases, signifying a pivotal development in nanomedicine for musculoskeletal therapeutics.
ETHAMOLIN® (Ethanolamine Oleate) Injection is a mild sclerosing agent. Chemically it is C17H33COOH•NH2CH2CH2OH. It has the following structure:

The empirical formula is C20H41NO3, representing a molecular weight of 343.55.

ETHAMOLIN Injection consists of ethanolamine, a basic substance, which when combined with oleic acid, forms a clear pale-yellow to straw-colored, deliquescent oleate. The pH ranges from 8.0 to 9.0.

ETHAMOLIN Injection is a sterile, apyrogenic, aqueous solution containing in each mL approximately 50 mg of ethanolamine oleate with benzyl alcohol 2% by volume as preservative.
Histone deacetylase 6 (HDAC6) has been shown to play an important role in allergic inflammation. This study hypothesized that novel downstream targets of HDAC6 would mediate allergic inflammation. Experiments employing HDAC6 knock out C57BL/6 mice showed that HDAC6 mediated passive cutaneous anaphylaxis (PCA) and passive systemic anaphylaxis (PSA). Antigen stimulation increased expression of N-myc (MYCN) and CXCL3 in an HDAC6-dependent manner in the bone marrow-derived mast cells. MYCN and CXCL3 were necessary for both PCA and PSA. The role of early growth response 3 (EGR3) in the regulation of HDAC6 expression has been reported. ChIP assays showed EGR3 as a direct regulator of MYCN. miR-34a-5p was predicted to be a negative regulator of MYCN. Luciferase activity assays showed miR-34a-5p as a direct regulator of MYCN. miR-34a-5p mimic negatively regulated PCA and PSA. MYCN decreased miR-34a-5p expression in antigen-stimulated rat basophilic leukemia cells (RBL2H3). MYCN was shown to bind to the promoter sequence of CXCL3. In an IgE-independent manner, recombinant CXCL3 protein increased expression of HDAC6, MYCN, and β-hexosaminidase activity in RBL2H3 cells. Mouse recombinant CXCL3 protein enhanced the angiogenic potential of the culture medium of RBL2H3. CXCL3 was necessary for the enhanced angiogenic potential of the culture medium of antigen-stimulated RBL2H3. The culture medium of RBL2H3 was able to induce M2 macrophage polarization in a CXCL3-dependent manner. Recombinant CXCL3 protein also increased the expression of markers of M2 macrophage. Thus, the identification of the novel role of HDAC6-MYCN-CXCL3 axis can help better understand the pathogenesis of anaphylaxis.
The invention discloses a flavivirus human monoclonal antibody and application, which belong to the technical field of medicine. According to the flavivirus human monoclonal antibody and the application provided by the invention, three antibodies capable of protein-binding with ZIKV-E are acquired, and binding sites of the three antibodies are confirmed. The three antibodies are completely different from a reported ZIKV antibody sequence, and are three new-found antibodies. The binding constants of the three antibodies and the ZIKV-E are 39.9pM (Z5), 44.7pM (Z6) and 200pM (Z7), which show that the three human monoclonal antibodies have a higher ZIKV-E protein-binding capacity. Through competiton experiments, the binding sites of the three antibodies have competitive relationships with 2A10G6, and the phenomenon shows that the binding sites of the three antibodies are near FL, and E protein of flaviviridae is highly conserved at the FL part. The antibody provided by the invention effectively detects the infection of common flaviviridae viruses: ZIKV, dengue 1-4 type and yellow fever viruses, and has huge application values on clinic detection and fundamental research.
One subcutaneous vaccination with rDEN1delta30 vaccine (10\^5 PFU dose) into the deltoid region of either arm. This arm may enroll after Arm 1 depending on the effect of the vaccine on subjects in Arm 1.
PURPOSE: The purpose of this study is to determine computed tomography (CT) findings that aid in differentiating idiopathic myointimal hyperplasia of mesenteric veins (IMHMV) from other colitides.
METHODS: Retrospective review of histiologic proven cases of IMHMV (n = 12) with contrast enhanced CT (n = 11) and/or computed tomography angiography (CTA) (n = 9) exams. Control groups comprised of CT of infectious colitis (n = 13), CT of inflammatory bowel disease (IBD) (n = 12), and CTA of other colitides (n = 13). CT exams reviewed by 2 blinded gastrointestinal radiologists for maximum bowel wall thickness, enhancement pattern, decreased bowel wall enhancement, submucosal attenuation value, presence and location of IMV occlusion, peripheral mesenteric venous occlusion, dilated pericolonic veins, subjective IMA dilation, maximum IMA diameter, maximum peripheral IMA branch diameter, ascites, and mesenteric edema. Presence of early filling veins was an additional finding evaluated on CTA exams.
RESULTS: Statistically significant CT findings of IMHMV compared to control groups included greater maximum bowel wall thickness, decreased bowel enhancement, IMV occlusion, and peripheral mesenteric venous occlusion (p < 0.05). Dilated pericolonic veins were seen more frequently in IMHMV compared to the infectious colitis group (64% versus 15%, p = 0.02). Additional statistically significant finding on CTA included early filling veins in IMHMV compared to the CTA control group (100% versus 46%, p = 0.008).
CONCLUSION: IMHMV is a rare chronic non-thrombotic ischemia predominantly involving the rectosigmoid colon. CT features that may aid in differentiating IMHMV from other causes of left-sided colitis include marked bowel wall thickening with decreased enhancement, IMV and peripheral mesenteric venous occlusion or tapering, and early filling of dilated veins on CTA.
Chronic diarrhoea is common and largely due to irritable bowel syndrome (IBS). IBS is reported to affect about 11% of the UK population. About half these patients are believed, however, to have bile acid diarrhoea (BAD). There are, therefore, more than one million patients with BAD in the UK. BAD is caused by small bowel malabsorption of bile acids (BA) and increased BA in the large intestine cause diarrhoea. Once diagnosed, the treatment of BAD is simple and effective. BAD, however, is often not diagnosed because of a lack of easily available and reliable diagnostic methods.

In the UK, the radiolabelled 23-seleno-25-homotaurocholic acid test (SeHCAT) is the gold-standard diagnostic method. The SeHCAT is performed by oral administration of a radiolabel, followed by two full-body scans, one week apart, to assess retention of BA. A low retention time indicates BAD. SeHCAT, however, is expensive, inconvenient to the patient, exposes the patient to radiation and has limited availability. A simple laboratory biomarker for the diagnosis of BAD is, therefore, desirable.

Proposed diagnostic laboratory biomarkers for BAD include measurement of faecal BA and serum 7a-hydroxy-4-cholesten-3-one (C4). C4, an intermediate in the BA synthesis pathway, is the common precursor for the primary BAs. It is, therefore, utilised as a biomarker of BA synthesis. Serum C4 increases in BAD, as BA synthesis increases to compensate for the increased faecal BA loss. C4 measurement requires a single serum sample for analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS). There is, however, limited data comparing its diagnostic accuracy to the SeHCAT scan. Furthermore, pre-analytical variables which may affect C4, include cholesterol lowering medication, diurnal variation and effects of food intake require clarification to optimise conditions for sample collection before its introduction into routine laboratory use. Literature suggests both diurnal variation and post-prandial response can influence C4 levels, however there is limited information on whether this is primarily a post-prandial response, or due to diurnal variation. This study aims to compare pre- and post-prandial C4 levels, controlled for diurnal variation.
9.1 Controlled Substance

Carisoprodol tablet contains carisoprodol, a Schedule IV controlled substance. Carisoprodol has been subject to abuse, misuse, and criminal diversion for nontherapeutic use [see Warnings and Precautions (5.2)].

9.2 Abuse

Abuse of carisoprodol poses a risk of overdosage which may lead to death, CNS and respiratory depression, hypotension, seizures and other disorders [see Warnings and Precautions (5.2) and Overdosage (10)]. Patients at high risk of carisoprodol abuse may include those with prolonged use of carisoprodol, with a history of drug abuse, or those who use carisoprodol in combination with other abused drugs.

Prescription drug abuse is the intentional non-therapeutic use of a drug, even once, for its rewarding psychological effects. Drug addiction, which develops after repeated drug abuse, is characterized by a strong desire to take a drug despite harmful consequences, difficulty in controlling its use, giving a higher priority to drug use than to obligations, increased tolerance, and sometimes physical withdrawal. Drug abuse and drug addiction are separate and distinct from physical dependence and tolerance (for example, abuse or addiction may not be accompanied by tolerance or physical dependence) [see Drug Abuse and Dependence (9.3)].

9.3 Dependence

Tolerance is when a patient’s reaction to a specific dosage and concentration is progressively reduced in the absence of disease progression, requiring an increase in the dosage to maintain the same. Physical dependence is characterized by withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Both tolerance and physical dependence have been reported with the prolonged use of carisoprodol. Reported withdrawal symptoms with carisoprodol include insomnia, vomiting, abdominal cramps, headache, tremors, muscle twitching, anxiety, ataxia, hallucinations, and psychosis. Instruct patients taking large doses of carisoprodol or those taking the drug for a prolonged time to not abruptly stop carisoprodol [see Warnings and Precautions (5.2)].
PURPOSE: An anti-cancer composition containing Lactobacillus casei spp. culture is provided to use as active ingredient for anti-cancer effect. CONSTITUTION: An anti-cancer composition contains Lactobacillus casei culture as an active ingredient. The cancer is gastric cancer, lung cancer, breast cancer, ovarian cancer, and colon cancer. A method for preparing the Lactobacillus casei culture comprise: a step of culturing Lactobacillus casei spp. in a medium containing carbon source, nitrogen source, and phosphorous source at 20°C to 45°C for 10 to 40 hours; and a step of removing Lactobacillus casei from the medium. The carbon source is glucose, sucrose, lactose, fructose, maltose, starch, cellulose, soybean milk, sun flower oil, castor oil, coconut oil, or acetic acid. The nitrogen source is peptone, yeast extract, meat juice, malt extract, corn steep liquid(CSL), urine, ammonium sulfate, ammonium chloride or ammonium nitrate. The phosphorus source is monobasic potassium phosphate, phosphate transport dipotasium, sodium dihydrogenphosphate or disodium hydrogen phosphate.
A total of 76 cases of deliberate or accidental overdosage with oral aripiprazole have been reported worldwide. These include overdoses with oral aripiprazole alone and in combination with other substances. No fatality was reported from these cases. Of the 44 cases with known outcome, 33 cases recovered without sequelae and one case recovered with sequelae (mydriasis and feeling abnormal). The largest known case of acute ingestion with a known outcome involved 1080 mg of oral aripiprazole (36 times the maximum recommended daily dose) in a patient who fully recovered. Included in the 76 cases are 10 cases of deliberate or accidental overdosage in children (age 12 and younger) involving oral aripiprazole ingestions up to 195 mg with no fatalities. 

Common adverse reactions (reported in at least 5% of all overdose cases) reported with oral aripiprazole overdosage (alone or in combination with other substances) include vomiting, somnolence, and tremor. Other clinically important signs and symptoms observed in one or more patients with aripiprazole overdoses (alone or with other substances) include acidosis, aggression, aspartate aminotransferase increased, atrial fibrillation, bradycardia, coma, confusional state, convulsion, blood creatine phosphokinase increased, depressed level of consciousness, hypertension, hypokalemia, hypotension, lethargy, loss of consciousness, QRS complex prolonged, QT prolonged, pneumonia aspiration, respiratory arrest, status epilepticus, and tachycardia.
A computer-implemented method and system for tracking skin concerns. Color-coded substrates come in different colors, each color being associate with a different skin concern. The color-coded substrates include at least one hydrocolloid and active agent. The color-coded substrates can come in different area-specific shapes for applying on different areas of the skin or face. The color-coded substrates can come in different dosages. A computing device, such as a smartphone, can be used to take scans of the skin with or without substrates, and the computing device is configured to analyze the skin and color-coded substrates based on color or shape or other symbols to make recommendations so that a subject will be able to track the progress of any skin concern.
Using a handheld device, subjects were perform 30 breaths a day, six days a week. The device produces resistance that increases the effort of breathing in. The resistance to breathing will be weak.
A method and system for defining, configuring, deploying, delivering, and monitoring health improvement programs are described. According to one embodiment, a method, comprises defining health improvement program components. The health improvement program components are assembled into a plurality of configured health improvement program templates. One or more program templates of the plurality of configured health improvement program templates are configured to meet the requirements of a given population. The one or more health improvement program templates are deployed to a plurality of program participants within the population. a personalized health improvement program is delivered for each participant of the plurality of program participants within the population. Participant progress is monitored.
PURPOSE: To obtain a bactericidal composition having low viscosity and excellent permeability and useful for external treatment of acne by containing a bactericide, a fatty acid and a fatty alcohol. CONSTITUTION: This acne treating agent contains a bactericide effective for killing an acne bacterium, a fatty acid (e.g. linoleic acid or linolenic acid) and a fatty alcohol (e.g. aqueous ethanol), and is preferably prepared to a shape of quick dispersal or extinction foam. The quick extinction foam agent is prepared by adding a quick extinction foaming agent, an aerosol spraying agent and an anticorrosive agent, as necessary, other than the above components. The bactericide is selected from parachlorometaxylenol, benzoyl peroxide, triclosan, sulfur, salicylic acid and their mixture. The treating agent contains 0.05-10wt.% of the bactericide, 0.5-5.0wt.% of the fatty acid and 40-90wt.% of the fatty alcohol.
All participants will be administered with the In-Ear and Wearable devices concurrently for 8 minutes while the application records the readings from the devices. Participants with the first glucometer reading of less than 11.1 mmol/L will be required to return one-hour post sugary drink consumption for a second reading with both devices.
FIELD: cosmetics. SUBSTANCE: the present innovation deals with hygiene and purification of skin. The suggested energetic cosmetic mask contains nipagin, nipasol, methyl-, propylarabens, glycerol, water, additionally, it contains bee wax, mineral oil - protein hydrolysate, isopropylmyristat, titanium dioxide, white clay, vitamins A, D, E, complex CO 2 -extract out of seeds of mustard, carrots and rice meal, coenzyme Q 10 , perfumery composition. Components are taken at certain quantitative ratio. Mask in question increases internal energy of cells and is of vitaminizing, regenerating, nourishing and hydrant action. EFFECT: higher efficiency. 6 tbl
The purpose of this pilot study is to conduct the investigation of the safety and efficacy of autologous cord blood infusion in premature neonates who demonstrate anemia due to prematurity (most common prematurity complication). However, premature infants reveal a high risk of other acute complications, including brain injury (e.g., intraventricular hemorrhage; IVH), necrotizing enterocolitis (NEC), and neonatal respiratory distress syndrome (RDS), as well as retinopathy of prematurity (ROP) and bronchopulmonary dysplasia (BPD). Therefore, prematurity is considered one of the main causes of neonatal deaths. The preterm neonates need transfusion of allogenic whole peripheral blood or any of its components at a time of anemia of prematurity development. In contrast, other prematurity complications do not have effective treatment nor preventive strategies. We will enroll premature neonates born premature (\<34 weeks of gestation) who developed anemia of prematurity and had their own autologous cord blood collected for subsequent transfusion. Next, we will test tolerability, safety and efficacy of autogenic whole cord blood infusion and evaluate the frequency of premature complications in neonates after transfusion. Besides, this pilot study will test feasibility of technical collection, preparation and infusion of a neonate's own umbilical cord blood within the first 5 days after birth.
The invention relates to a preparation method of the derivative of memantine hydrochloride alkyl 2-sulfer 2-nitrogen. The method belongs to the technical field of synthesis of marking precursor compound for radiopharmaceutical. The invention provides a preparation method of N-[-(N-2-thiolethy)) amino acetyl]-(2- thiolethy)-3, 5-NCAM to prepare the radiopharmaceutical of <99m>Tc-NCAM marked by technetium which is used for image display of a brain receptor. Being approved by experiment, the NCAM meets the requirements of permeability about blood brain barrier (BBB) in the aspects such as electroneutrality, molecule size and lipid solubility (LogP). After being mixed with other adjuvant drug and frozen, the NACM is easy to produce a medicine box with good stability and a marking rate of above 95 percent. The prepared <99m>Tc-NCAM is tested by an animal distribution in mouse and radiation self-developing test, and the result is that the <99m>Tc-NCAM concentrates on the striaturn and hippocampus of the mouse. With high safety in animal test, the invention is a potential developer of the brain receptor.